Samiee-Zafarghandy, S
,
van den Anker, J N
Laughon, M M
Clark, R H
Smith, P B
Hornik, C P
Article History
Received: 27 May 2015
Revised: 2 September 2015
Accepted: 8 September 2015
First Online: 22 October 2015
Competing interests
: Dr Smith receives salary support for research from the National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences of the NIH (UL1TR001117), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (HHSN275201000003I and 1R01-HD081044-01) and the Food and Drug Administration (1R18-FD005292-01); he also receives research support from Cempra Pharmaceuticals (subaward to HHS0100201300009C) and industry for neonatal and pediatric drug development (ExternalRef removed). Dr van den Anker receives salary support for research from the NIH (5K24DA027992, 5U54HD071601, 5R01HD060543). Dr Hornik receives salary support for research from the National Center for Advancing Translational Sciences of the NIH (UL1TR001117). Dr Laughon receives support from the US government for his work in pediatric and neonatal clinical pharmacology (HHSN267200700051C, PI: Benjamin, under the Best Pharmaceuticals for Children Act) and from the NICHD (5K23HD068497-01). The other authors declare no conflict of interest.
Free to read: This content has been made available to all.